Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Michael.James.Clark
    Senior Member
    • Apr 2009
    • 207

    #1

    Complete Genomics User Group Meeting

    Just got back from the Complete Genomics User Group Meeting in San Francisco. Hopefully we'll start seeing some discussion of Complete data here on SEQanswers in the near future.

    I have yet to take a close look at our data back from Complete yet, but I now have a much stronger understanding of their bioinformatics and technical pipeline (you can get their biochemistry info from their white paper). Anyone else here get data from them or attend the meeting?

    I think CGA tools is very powerful for small variant detection. It looked from the data presented (again, preliminary) that their variant detection accuracy is on par or a little better than what is generally seen with Illumina or SOLiD whole genome data.

    Given the nature of their data, converting to BAM and doing alternative variant analysis may not be as powerful (this is something we users may have to try). This is because they do assembly over non-reference called positions in their data processing. It will be interesting to see how their variant detection performance compares to variants detected on other platforms and with other analysis platforms.

    They are just starting to produce CNV and SV calls. These data I'm not sure about yet, but it is good to see them diving into it with both feet because these variants are at least as important as small variants from a whole genome perspective.

    They are also heading towards in-house somatic variants analysis (comparing two genomes), which is pretty important for cancer genomics. It will be interested to see what is delivered there in the future. Right now, the CGAtools calldiff algorithm is used for this. I'd like to hear opinions on calldiff from people who've used it.

    Here's a pic of their machines in action:

    It's apparently 80% humidity and hot in that room. Yes, it's a dark room. This is because it's the optimal environment for the DNBs (DNA nano-balls) and for the picoliter quantities of reagents used at each cycle. (Later on, we had a rave party in there when the sequencers were on their lunch break!)

    Here's one of their slides:


    Complete Genomics may be a strong way to go in the near future for whole genome sequencing. I'd certainly consider it as an alternative to doing it in-house at this point, freeing up local machines for targeted pull-downs, exomes, non-human, RNAseq, ChIPseq, etc.

    I look forward to hearing from other Complete Genomics users in the future.
    Mendelian Disorder: A blogshare of random useful information for general public consumption. [Blog]
    Breakway: A Program to Identify Structural Variations in Genomic Data [Website] [Forum Post]
    Projects: U87MG whole genome sequence [Website] [Paper]
  • rskr
    Senior Member
    • Oct 2010
    • 249

    #2
    Reference dependence is the impression that Complete Genomics gives. Population level or cancer genomics could be problematic for that platform, which would be sad given that is the market they want. We will see after their cancer research grants.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    18 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-13-2026, 09:56 AM
    0 responses
    22 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-09-2026, 11:14 AM
    0 responses
    28 views
    0 reactions
    Last Post SEQadmin2  
    Working...